ArticleViruses2026
Externally Validated Probabilistic Modeling of a Predefined Entecavir Resistance Pathway in HBV Using Independent Public Repositories.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate interpretation of hepatitis B virus (HBV) polymerase sequences is essential for identifying antiviral resistance, particularly for high-genetic-barrier agents such as entecavir. Current resistance interpretation relies largely on deterministic rule-based systems that do not quantify uncertainty and are difficult to evaluate across independent datasets. We aimed to develop and externally validate a transparent probabilistic framework for reconstructing a predefined entecavir resistance pathway from HBV polymerase sequences.
methodsHBV polymerase sequences were retrieved from the NCBI GenBank database and curated through translation, quality control, and deduplication to create the development dataset. Reverse transcriptase (RT) positions were indexed using motif-anchored numbering based on the YMDD-family motif. A genotypic proxy for the entecavir resistance pathway was defined by lamivudine-associated background substitutions combined with entecavir-associated RT substitutions. A logistic regression model with probability calibration was trained and internally validated using prespecified performance metrics and thresholds. External validation was performed on an independent HBVdb dataset with preprocessing, model parameters, and thresholds frozen prior to evaluation.
resultsThe development dataset comprised 1174 unique polymerase sequences, of which 268 met the resistance pathway definition. Internal validation demonstrated perfect discrimination, consistent with the deterministic genotypic definition of the outcome. External validation on 11,513 independent HBVdb sequences demonstrated reproducible performance across repositories despite a markedly lower prevalence of the resistance pathway (2.2%), with preserved discrimination and stable threshold-based performance.
conclusionsThis study presents a transparent and externally validated machine learning framework for probabilistic identification of the entecavir resistance pathway in HBV. The approach provides a transparent and reproducible probabilistic formalization of an established genotypic resistance definition and may serve as a methodological framework for standardized sequence-based resistance interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.